Drugs / JKN24011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07440524 | Aug 2024 → Apr 2026 overdue | chronic obstructive pulmonary disease | Joincare Pharmaceutical Group Industry Co., Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JKN24011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07440524 ↗ |
| Route | Subcutaneous | “JKN24011 subcutaneous injection,Q4W” NCT07440524 ↗ |
| Target | TSLP | “JKN24011 targets TSLP” NCT07440524 ↗ |